source
- Alnylam, Inceptive ink AI deal potentially worth $2BThe RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.BioPharma Dive · 1mo ago↗ source
- STAT+: AI titans push Congress for DNA safeguardsInceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The ReadoutSTAT · 1mo ago↗ source
- STAT+: Utah Medical Board scolded for going rogue with AI criticismIn this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.STAT · 1mo ago↗ source